{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:26:49Z","timestamp":1794428809026,"version":"4.9.1"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The field of human induced pluripotent stem cell (hiPSC)-derived cell therapies is rapidly advancing, offering a promising \u201coff-the-shelf\u201d approach for treating both solid and hematologic malignancies. Among these, hiPSC-derived Natural Killer (NK) cell therapies have gained significant traction, with several currently in clinical trials and development. NK cell-based immunotherapy has emerged as a safe and effective strategy for patients with advanced leukemia, and ongoing research is focused on optimizing its accessibility, scalability, and efficacy. A key advantage of hiPSC-derived NK cells is their genetic susceptibility, allowing for targeted enhancements in fitness, metabolism, specificity, and cytotoxicity. This overcomes the donor-dependent variability that limits autologous and allogeneic NK cell therapies, which often struggle with expansion and functional consistency. Despite their promise, hiPSC-derived NK cells present unique manufacturing challenges, requiring precise optimization to ensure reproducibility, safety, and clinical-grade scalability. In this review, we will explore what we believe to be the most impactful genetic engineering strategies to enhance hiPSC-derived NK cell function. Additionally, we will also discuss the major hurdles challenging widespread clinical adoption, including licensing constraints, production yield, regulatory ambiguities, and the complexities of multi-step genetic engineering and safety validation. Finally, we will outline the emerging therapeutic pipelines from leading biotech companies, providing a valuable and up-to-date overview of the future landscape of hiPSC-derived NK cell therapy.<\/jats:p>","DOI":"10.1186\/s13046-025-03558-6","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:32:27Z","timestamp":1766997147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Challenges and opportunities of human iPSC-derived NK as \u201cOff-the-shelf\u201d cellular therapies"],"prefix":"10.1186","volume":"44","author":[{"given":"Nicola","family":"Romanini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratchapong","family":"Netsrithong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Themeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Tazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"3558_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","volume":"21","author":"CJ Bashor","year":"2022","unstructured":"Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veiseh O. Engineering the next generation of cell-based therapeutics. Nat Rev Drug Discov. 2022;21:655\u201375.","journal-title":"Nat Rev Drug Discov"},{"key":"3558_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2022016204","volume":"141","author":"W Qasim","year":"2023","unstructured":"Qasim W. Genome-edited allogeneic donor universal chimeric antigen receptor T cells. Blood. 2023;141:835\u201345.","journal-title":"Blood"},{"key":"3558_CR3","doi-asserted-by":"publisher","unstructured":"Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat Med. 2025.\u00a0https:\/\/doi.org\/10.1038\/s41591-024-03449-x.","DOI":"10.1038\/s41591-024-03449-x"},{"key":"3558_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856\u201368.","journal-title":"Blood"},{"key":"3558_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki A-M, Liu H, \u00d6zkazanc D, Ku\u010derov\u00e1 L, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15:164.","journal-title":"J Hematol Oncol"},{"key":"3558_CR6","doi-asserted-by":"publisher","first-page":"992232","DOI":"10.3389\/fimmu.2022.992232","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Song W, Li Z, Zhang M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front Immunol. 2022;13:992232.","journal-title":"Front Immunol"},{"key":"3558_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"3558_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"3558_CR9","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on Off-The-Shelf allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"key":"3558_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557\u201375.","journal-title":"Nat Rev Cancer"},{"key":"3558_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2141.2009.07768.x","volume":"147","author":"MR Verneris","year":"2009","unstructured":"Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol. 2009;147:185\u201391.","journal-title":"Br J Haematol"},{"key":"3558_CR12","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3389\/fimmu.2019.02045","volume":"10","author":"F Bozzano","year":"2019","unstructured":"Bozzano F, Perrone C, Moretta L, De Maria A. NK cell precursors in human bone marrow in health and inflammation. Front Immunol. 2019;10:2045.","journal-title":"Front Immunol"},{"key":"3558_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25:451\u20137.","journal-title":"Cytotherapy"},{"key":"3558_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri.2015.9","volume":"16","author":"A Cerwenka","year":"2016","unstructured":"Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16:112\u201323.","journal-title":"Nat Rev Immunol"},{"key":"3558_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u201376.","journal-title":"Cell"},{"key":"3558_CR16","doi-asserted-by":"publisher","first-page":"103017","DOI":"10.1016\/j.scr.2023.103017","volume":"67","author":"S Okura","year":"2023","unstructured":"Okura S, Ishii H, Suzuki A, Saegusa C, Fujiki K, Sugano K, et al. Generation of two induced pluripotent stem cell lines from individuals without auditory disorders. Stem Cell Res. 2023;67:103017.","journal-title":"Stem Cell Res"},{"key":"3558_CR17","doi-asserted-by":"publisher","first-page":"e13256","DOI":"10.1111\/cpr.13256","volume":"55","author":"ATL Lam","year":"2022","unstructured":"Lam ATL, Ho V, Vassilev S, Reuveny S, Oh SKW. An allied reprogramming, selection, expansion and differentiation platform for creating HiPSC on microcarriers. Cell Prolif. 2022;55:e13256.","journal-title":"Cell Prolif"},{"key":"3558_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/biores.2019.0046","volume":"9","author":"A Al Abbar","year":"2020","unstructured":"Al Abbar A, Ngai SC, Nograles N, Alhaji SY, Abdullah S. Induced pluripotent stem cells: reprogramming platforms and applications in cell replacement therapy. Biores Open Access. 2020;9:121\u201336.","journal-title":"Biores Open Access"},{"key":"3558_CR19","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.crmeth.2022.100317","volume":"2","author":"A Kunitomi","year":"2022","unstructured":"Kunitomi A, Hirohata R, Arreola V, Osawa M, Kato TM, Nomura M, et al. Improved Sendai viral system for reprogramming to Naive pluripotency. Cell Rep Methods. 2022;2:100317.","journal-title":"Cell Rep Methods"},{"key":"3558_CR20","doi-asserted-by":"publisher","unstructured":"Tominaga S, Ojima T, Miyazawa M, Iwamoto H, Kitadani J, Maruoka S, et al. Induced pluripotent stem cell-derived dendritic cell vaccine therapy genetically modified on the ubiquitin-proteasome system. Gene Ther. 2023.\u00a0https:\/\/doi.org\/10.1038\/s41434-023-00388-z.","DOI":"10.1038\/s41434-023-00388-z"},{"key":"3558_CR21","first-page":"24","volume":"7","author":"T Ueda","year":"2023","unstructured":"Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2023;7:24\u201337.","journal-title":"Nat Biomed Eng"},{"key":"3558_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-023-01406-8","volume":"16","author":"Q Huang","year":"2023","unstructured":"Huang Q, Zhang X-H, Liu D. CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH annual meeting. J Hematol Oncol. 2023;16:18.","journal-title":"J Hematol Oncol"},{"key":"3558_CR23","doi-asserted-by":"publisher","first-page":"893928","DOI":"10.3389\/fonc.2022.893928","volume":"12","author":"J He","year":"2022","unstructured":"He J, Xu N, Zhou H, Zhou Y, Wu D, Zhao R, et al. Case report: chimeric antigen receptor T cells induced late severe cytokine release syndrome. Front Oncol. 2022;12:893928.","journal-title":"Front Oncol"},{"key":"3558_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022;10:12.","journal-title":"Biomark Res"},{"key":"3558_CR25","doi-asserted-by":"publisher","unstructured":"Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022;132.\u00a0https:\/\/doi.org\/10.1172\/JCI154334.","DOI":"10.1172\/JCI154334"},{"key":"3558_CR26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcyt.2020.03.432","volume":"22","author":"RMT Ten Ham","year":"2020","unstructured":"Ten Ham RMT, H\u00f6vels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH, et al. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy. 2020;22:388\u201397.","journal-title":"Cytotherapy"},{"key":"3558_CR27","doi-asserted-by":"publisher","unstructured":"Gutbier S, Wanke F, Dahm N, R\u00fcmmelin A, Zimmermann S, Christensen K, et al. Large-Scale production of human iPSC-Derived macrophages for drug screening. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21134808.","DOI":"10.3390\/ijms21134808"},{"key":"3558_CR28","doi-asserted-by":"publisher","unstructured":"Gurney M, O\u2019Dwyer M. Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia. Cancers (Basel). 2021;13.\u00a0https:\/\/doi.org\/10.3390\/cancers13071568.","DOI":"10.3390\/cancers13071568"},{"key":"3558_CR29","doi-asserted-by":"publisher","first-page":"e1151","DOI":"10.1002\/cti2.1151","volume":"9","author":"B Foley","year":"2020","unstructured":"Foley B, Ta C, Barnes S, de Jong E, Nguyen M, Cheung LC, et al. Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia. Clin Transl Immunol. 2020;9:e1151.","journal-title":"Clin Transl Immunol"},{"key":"3558_CR30","doi-asserted-by":"publisher","first-page":"765705","DOI":"10.3389\/fimmu.2021.765705","volume":"12","author":"SA Barnes","year":"2021","unstructured":"Barnes SA, Trew I, de Jong E, Foley B. Making a killer: selecting the optimal natural killer cells for improved immunotherapies. Front Immunol. 2021;12:765705.","journal-title":"Front Immunol"},{"key":"3558_CR31","doi-asserted-by":"publisher","first-page":"200870","DOI":"10.1016\/j.omton.2024.200870","volume":"32","author":"AA van Vliet","year":"2024","unstructured":"van Vliet AA, van den Hout MGCN, Steenmans D, Duru AD, Georgoudaki A-M, de Gruijl TD, et al. Bulk and single-cell transcriptomics identify gene signatures of stem cell-derived NK cell donors with superior cytolytic activity. Mol Ther Oncol. 2024;32:200870.","journal-title":"Mol Ther Oncol"},{"key":"3558_CR32","doi-asserted-by":"publisher","first-page":"lnae032","DOI":"10.1093\/lifemedi\/lnae032","volume":"3","author":"L Zhang","year":"2024","unstructured":"Zhang L, Weiskittel TM, Zhu Y, Xue D, Zhang H, Shen Y, et al. Comparative dissection of transcriptional landscapes of human iPSC-NK differentiation and NK cell development. Life Med. 2024;3:lnae032.","journal-title":"Life Med"},{"key":"3558_CR33","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3389\/fimmu.2019.02078","volume":"10","author":"F Cichocki","year":"2019","unstructured":"Cichocki F, Grzywacz B, Miller JS. Human NK cell development: one road or many? Front Immunol. 2019;10:2078.","journal-title":"Front Immunol"},{"key":"3558_CR34","doi-asserted-by":"publisher","first-page":"841107","DOI":"10.3389\/fimmu.2022.841107","volume":"13","author":"BH Goldenson","year":"2022","unstructured":"Goldenson BH, Hor P, Kaufman DS. iPSC-Derived natural killer cell Therapies - Expansion and targeting. Front Immunol. 2022;13:841107.","journal-title":"Front Immunol"},{"key":"3558_CR35","doi-asserted-by":"publisher","unstructured":"Judge SJ, Purl MC, Murphy WJ, Canter RJ. What\u2019s in a name? Memory NK cells for cancer immunotherapy. J Immunother Cancer. 2025;13.\u00a0https:\/\/doi.org\/10.1136\/jitc-2024-010850.","DOI":"10.1136\/jitc-2024-010850"},{"key":"3558_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41590-022-01327-7","volume":"23","author":"T R\u00fcckert","year":"2022","unstructured":"R\u00fcckert T, Lareau CA, Mashreghi M-F, Ludwig LS, Romagnani C. Clonal expansion and epigenetic inheritance of long-lasting NK cell memory. Nat Immunol. 2022;23:1551\u201363.","journal-title":"Nat Immunol"},{"key":"3558_CR37","doi-asserted-by":"publisher","unstructured":"Arellano-Ballestero H, Zubiak A, Dally C, Orchard K, Alrubayyi A, Charalambous X et al. Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy. J Immunother Cancer. 2024;12.\u00a0https:\/\/doi.org\/10.1136\/jitc-2023-008717.","DOI":"10.1136\/jitc-2023-008717"},{"key":"3558_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/ni1332","volume":"7","author":"JG O\u2019Leary","year":"2006","unstructured":"O\u2019Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol. 2006;7:507\u201316.","journal-title":"Nat Immunol"},{"key":"3558_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","volume":"457","author":"JC Sun","year":"2009","unstructured":"Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009;457:557\u201361.","journal-title":"Nature"},{"key":"3558_CR40","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1073\/pnas.0813192106","volume":"106","author":"MA Cooper","year":"2009","unstructured":"Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA. 2009;106:1915\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3558_CR41","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012;120:4751\u201360.","journal-title":"Blood"},{"key":"3558_CR42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ni.3227","volume":"16","author":"RK Reeves","year":"2015","unstructured":"Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, et al. Antigen-specific NK cell memory in rhesus macaques. Nat Immunol. 2015;16:927\u201332.","journal-title":"Nat Immunol"},{"key":"3558_CR43","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123.","journal-title":"Sci Transl Med"},{"key":"3558_CR44","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","volume":"139","author":"JJ Bednarski","year":"2022","unstructured":"Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022;139:1670\u201383.","journal-title":"Blood"},{"key":"3558_CR45","doi-asserted-by":"publisher","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","volume":"14","author":"MM Berrien-Elliott","year":"2022","unstructured":"Berrien-Elliott MM, Foltz JA, Russler-Germain DA, Neal CC, Tran J, Gang M, et al. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci Transl Med. 2022;14:eabm1375.","journal-title":"Sci Transl Med"},{"key":"3558_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2020.11.003","volume":"57","author":"M Gang","year":"2020","unstructured":"Gang M, Wong P, Berrien-Elliott MM, Fehniger TA. Memory-like natural killer cells for cancer immunotherapy. Semin Hematol. 2020;57:185\u201393.","journal-title":"Semin Hematol"},{"key":"3558_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature09342","volume":"467","author":"K Kim","year":"2010","unstructured":"Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467:285\u201390.","journal-title":"Nature"},{"key":"3558_CR48","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1002\/mco2.626","volume":"5","author":"D Wang","year":"2024","unstructured":"Wang D, Dou L, Sui L, Xue Y, Xu S. Natural killer cells in cancer immunotherapy. MedComm. 2024;5:e626.","journal-title":"MedComm"},{"key":"3558_CR49","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1002\/mco2.553","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Shi Q, Wang P, Huang C, Tang S, Zhou M, et al. iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation. MedComm. 2024;5:e553.","journal-title":"MedComm"},{"key":"3558_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3558_CR51","doi-asserted-by":"publisher","first-page":"1081546","DOI":"10.3389\/fimmu.2022.1081546","volume":"13","author":"K Yang","year":"2022","unstructured":"Yang K, Zhao Y, Sun G, Zhang X, Cao J, Shao M, et al. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Front Immunol. 2022;13:1081546.","journal-title":"Front Immunol"},{"key":"3558_CR52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","volume":"114","author":"A Biederst\u00e4dt","year":"2021","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021;114:554\u201371.","journal-title":"Int J Hematol"},{"key":"3558_CR53","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol. 2021;10:e1274.","journal-title":"Clin Transl Immunol"},{"key":"3558_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CM9.0000000000002513","volume":"136","author":"X Deng","year":"2023","unstructured":"Deng X, Zhou J, Cao Y. Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells. Chin Med J. 2023;136:127\u201337.","journal-title":"Chin Med J"},{"key":"3558_CR55","doi-asserted-by":"publisher","unstructured":"Morton LT, Wachsmann TLA, Meeuwsen MH, Wouters AK, Remst DFG, van Loenen MM et al. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. J Immunother Cancer. 2022;10.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003715.","DOI":"10.1136\/jitc-2021-003715"},{"key":"3558_CR56","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00262-022-03275-5","volume":"72","author":"S Li","year":"2023","unstructured":"Li S, Zhang C, Shen L, Teng X, Xiao Y, Yu B, et al. TCR extracellular domain genetically linked to CD28, 2B4\/41BB and DAP10\/CD3\u03b6 -engineered NK cells mediates antitumor effects. Cancer Immunol Immunother. 2023;72:769\u201374.","journal-title":"Cancer Immunol Immunother"},{"issue":"Supplement 1","key":"3558_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-134625","volume":"136","author":"C Bachier","year":"2020","unstructured":"Bachier C, Borthakur G, Hosing C, Blum W, Rotta M, Ojeras P, et al. A phase 1 study of NKX101, an allogeneic CAR natural killer (NK) cell Therapy, in subjects with Relapsed\/Refractory (R\/R) acute myeloid leukemia (AML) or Higher-Risk myelodysplastic syndrome (MDS). Blood. 2020;136(Supplement 1):42\u20133.","journal-title":"Blood"},{"key":"3558_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","volume":"13","author":"PR Kennedy","year":"2022","unstructured":"Kennedy PR, Felices M, Miller JS. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. Stem Cell Res Ther. 2022;13:165.","journal-title":"Stem Cell Res Ther"},{"key":"3558_CR59","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fimmu.2019.01262","volume":"10","author":"E Levy","year":"2019","unstructured":"Levy E, Reger R, Segerberg F, Lambert M, Leijonhufvud C, Baumer Y, et al. Enhanced bone marrow homing of natural killer cells following mRNA transfection with Gain-of-Function variant CXCR4R334X. Front Immunol. 2019;10:1262.","journal-title":"Front Immunol"},{"key":"3558_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-017-0275-9","volume":"5","author":"V Kremer","year":"2017","unstructured":"Kremer V, Ligtenberg MA, Zendehdel R, Seitz C, Duivenvoorden A, Wennerberg E, et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer. 2017;5:73.","journal-title":"J Immunother Cancer"},{"key":"3558_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","volume":"16","author":"YY Ng","year":"2020","unstructured":"Ng YY, Tay JCK, Wang S. CXCR1 expression to improve Anti-Cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther Oncolytics. 2020;16:75\u201385.","journal-title":"Mol Ther Oncolytics"},{"key":"3558_CR62","doi-asserted-by":"publisher","first-page":"647358","DOI":"10.3389\/fimmu.2021.647358","volume":"12","author":"MJ Shannon","year":"2021","unstructured":"Shannon MJ, Mace EM. Natural killer cell integrins and their functions in tissue residency. Front Immunol. 2021;12:647358.","journal-title":"Front Immunol"},{"key":"3558_CR63","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev. 2023;60:101073.","journal-title":"Blood Rev"},{"key":"3558_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","volume":"38","author":"Y Guo","year":"2017","unstructured":"Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15\/IL-15R\u03b1 complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10\u201321.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3558_CR65","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","volume":"13","author":"F Cichocki","year":"2022","unstructured":"Cichocki F, Bjordahl R, Goodridge JP, Mahmood S, Gaidarova S, Abujarour R, et al. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nat Commun. 2022;13:7341.","journal-title":"Nat Commun"},{"key":"3558_CR66","doi-asserted-by":"publisher","unstructured":"Zhou Y, Husman T, Cen X, Tsao T, Brown J, Bajpai A, et al. Interleukin 15 in Cell-Based cancer immunotherapy. Int J Mol Sci. 2022;23.\u00a0https:\/\/doi.org\/10.3390\/ijms23137311.","DOI":"10.3390\/ijms23137311"},{"key":"3558_CR67","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1089\/jir.2021.0078","volume":"41","author":"L Gao","year":"2021","unstructured":"Gao L, Yang L, Zhang S, Ge Z, Su M, Shi Y, et al. Engineering NK-92 cell by upregulating CXCR2 and IL-2 via CRISPR-Cas9 improves its antitumor effects as cellular immunotherapy for human colon cancer. J Interferon Cytokine Res. 2021;41:450\u201360.","journal-title":"J Interferon Cytokine Res"},{"key":"3558_CR68","doi-asserted-by":"publisher","first-page":"eadn1849","DOI":"10.1126\/sciadv.adn1849","volume":"10","author":"PR Kennedy","year":"2024","unstructured":"Kennedy PR, Arvindam US, Phung SK, Ettestad B, Feng X, Li Y, et al. Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments. Sci Adv. 2024;10:eadn1849.","journal-title":"Sci Adv"},{"key":"3558_CR69","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13287-021-02377-8","volume":"12","author":"C Choi","year":"2021","unstructured":"Choi C, Finlay DK. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. Stem Cell Res Ther. 2021;12:320.","journal-title":"Stem Cell Res Ther"},{"key":"3558_CR70","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41590-023-01462-9","volume":"24","author":"X Zheng","year":"2023","unstructured":"Zheng X, Hou Z, Qian Y, Zhang Y, Cui Q, Wang X, et al. Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nat Immunol. 2023;24:802\u201313.","journal-title":"Nat Immunol"},{"key":"3558_CR71","doi-asserted-by":"publisher","first-page":"46153","DOI":"10.1038\/srep46153","volume":"7","author":"WS Kim","year":"2017","unstructured":"Kim WS, Kim MJ, Kim DO, Byun J-E, Huy H, Song HY, et al. Suppressor of cytokine signaling 2 negatively regulates NK cell differentiation by inhibiting JAK2 activity. Sci Rep. 2017;7:46153.","journal-title":"Sci Rep"},{"key":"3558_CR72","doi-asserted-by":"publisher","first-page":"727987","DOI":"10.3389\/fmed.2021.727987","volume":"8","author":"ML Sobah","year":"2021","unstructured":"Sobah ML, Liongue C, Ward AC. SOCS proteins in Immunity, inflammatory Diseases, and Immune-Related cancer. Front Med (Lausanne). 2021;8:727987.","journal-title":"Front Med (Lausanne)"},{"key":"3558_CR73","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cyto.2018.03.033","volume":"118","author":"N Keating","year":"2019","unstructured":"Keating N, Nicholson SE. SOCS-mediated Immunomodulation of natural killer cells. Cytokine. 2019;118:64\u201370.","journal-title":"Cytokine"},{"key":"3558_CR74","doi-asserted-by":"publisher","unstructured":"Bernard P-L, Delconte R, Pastor S, Laletin V, Costa Da Silva C, Goubard A et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J Immunother Cancer. 2022;10.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-004244.","DOI":"10.1136\/jitc-2021-004244"},{"key":"3558_CR75","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic reprograming via deletion of CISH in human iPSC-Derived NK cells promotes in vivo persistence and enhances Anti-tumor activity. Cell Stem Cell. 2020;27:224\u2013e2376.","journal-title":"Cell Stem Cell"},{"key":"3558_CR76","doi-asserted-by":"publisher","unstructured":"Acosta JC, Bahr JM, Basu S, O\u2019Donnell JT, Barua A. Expression of CISH, an inhibitor of NK cell Function, increases in association with ovarian cancer development and progression. Biomedicines. 2023;11.\u00a0https:\/\/doi.org\/10.3390\/biomedicines11020299.","DOI":"10.3390\/biomedicines11020299"},{"key":"3558_CR77","doi-asserted-by":"publisher","unstructured":"Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB et al. Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021;131.\u00a0https:\/\/doi.org\/10.1172\/JCI142116.","DOI":"10.1172\/JCI142116"},{"key":"3558_CR78","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.crmeth.2024.100857","volume":"4","author":"A-P Chen","year":"2024","unstructured":"Chen A-P, Gao P, Lin L, Ashok P, He H, Ma C, et al. An improved approach to generate IL-15+\/+\/TGF\u03b2R2-\/- iPSC-derived natural killer cells using TALEN. Cell Rep Methods. 2024;4:100857.","journal-title":"Cell Rep Methods"},{"key":"3558_CR79","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31:1327\u2013e13435.","journal-title":"Cell Stem Cell"},{"key":"3558_CR80","doi-asserted-by":"publisher","first-page":"852436","DOI":"10.3389\/fimmu.2022.852436","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Cao K, Liu S, Xu Y, Tang L. Tim-3 expression causes NK cell dysfunction in type 2 diabetes patients. Front Immunol. 2022;13:852436.","journal-title":"Front Immunol"},{"key":"3558_CR81","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723\u201332.","journal-title":"Nat Immunol"},{"key":"3558_CR82","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","volume":"15","author":"KB Lupo","year":"2024","unstructured":"Lupo KB, Yao X, Borde S, Wang J, Torregrosa-Allen S, Elzey BD, et al. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy. Nat Commun. 2024;15:1909.","journal-title":"Nat Commun"},{"key":"3558_CR83","first-page":"150","volume":"26","author":"N Parvini","year":"2024","unstructured":"Parvini N, Akbari ME, Hamidieh AA, Fathi F, Amini AA, Ebrahimi M, et al. CTLA-4 Blockade of natural killer cells increases cytotoxicity against acute lymphoid leukaemia cells Neda. Cell J. 2024;26:150\u20137.","journal-title":"Cell J"},{"key":"3558_CR84","doi-asserted-by":"publisher","first-page":"200885","DOI":"10.1016\/j.omton.2024.200885","volume":"32","author":"D Kwon","year":"2024","unstructured":"Kwon D, Moon BK, Han M, Lee T-W, Lee J, Kang K-S. Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapy. Mol Ther Oncol. 2024;32:200885.","journal-title":"Mol Ther Oncol"},{"key":"3558_CR85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol Ther. 2020;28:52\u201363.","journal-title":"Mol Ther"},{"key":"3558_CR86","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00262-022-03317-y","volume":"72","author":"KH Susek","year":"2023","unstructured":"Susek KH, Schwietzer YA, Karvouni M, Gilljam M, Keszei M, Hussain A, et al. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated Inhibition in cancer immunotherapy. Cancer Immunol Immunother. 2023;72:1153\u201367.","journal-title":"Cancer Immunol Immunother"},{"key":"3558_CR87","doi-asserted-by":"publisher","unstructured":"Leem G, Jang S-I, Cho J-H, Jo JH, Lee HS, Chung MJ et al. Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with Chemotherapy-Refractory biliary tract cancer: A multicenter Open-Label phase 1\/2a trial. Cancers (Basel). 2022;14.\u00a0https:\/\/doi.org\/10.3390\/cancers14174229.","DOI":"10.3390\/cancers14174229"},{"key":"3558_CR88","doi-asserted-by":"publisher","unstructured":"Fisher JG, Doyle ADP, Graham LV, Khakoo SI, Blunt MD. Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines (Basel). 2022;10.\u00a0https:\/\/doi.org\/10.3390\/vaccines10121993.","DOI":"10.3390\/vaccines10121993"},{"key":"3558_CR89","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of Circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41:272\u2013e2879.","journal-title":"Cancer Cell"},{"key":"3558_CR90","doi-asserted-by":"publisher","first-page":"586168","DOI":"10.3389\/fimmu.2020.586168","volume":"11","author":"K Hoerster","year":"2020","unstructured":"Hoerster K, Uhrberg M, Wiek C, Horn PA, Hanenberg H, Heinrichs S. HLA class I knockout converts allogeneic primary NK cells into suitable effectors for Off-the-Shelf immunotherapy. Front Immunol. 2020;11:586168.","journal-title":"Front Immunol"},{"key":"3558_CR91","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell. 2019;24:566\u2013e5787.","journal-title":"Cell Stem Cell"},{"key":"3558_CR92","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Y, He X, Mo Z, Zhao M, Liang X, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell Rep Med. 2025;6:101889.","journal-title":"Cell Rep Med"},{"key":"3558_CR93","doi-asserted-by":"publisher","unstructured":"Clara JA, Levy ER, Reger R, Barisic S, Chen L, Cherkasova E et al. High-affinity CD16 integration into a CRISPR\/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells. J Immunother Cancer. 2022;10.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003804.","DOI":"10.1136\/jitc-2021-003804"},{"key":"3558_CR94","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/JLB.2MR1218-501R","volume":"105","author":"J Wu","year":"2019","unstructured":"Wu J, Mishra HK, Walcheck B. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy. J Leukoc Biol. 2019;105:1297\u2013303.","journal-title":"J Leukoc Biol"},{"issue":"Supplement 1","key":"3558_CR95","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-137766","volume":"136","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Blum R, Kaufman DS. ADAM17-Deficient pluripotent stem Cell-Derived natural killer cells possess improved Antibody-Dependent cellular cytotoxicity and antitumor activity. Blood. 2020;136(Supplement 1):2\u20132.","journal-title":"Blood"},{"key":"3558_CR96","doi-asserted-by":"publisher","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025.\u00a0https:\/\/doi.org\/10.1038\/s41591-025-03640-8.","DOI":"10.1038\/s41591-025-03640-8"},{"key":"3558_CR97","unstructured":"ResearchAndMarkets.com\u2019s. Growth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024\u20132035: A Forecasted $5.6 Billion Landscape. https:\/\/www.globenewswire.com\/; 2025. https:\/\/www.globenewswire.com\/news-release\/2025\/01\/08\/3006382\/28124\/en\/Growth-Trends-in-the-Induced-Pluripotent-Stem-Cells-iPSCs-Market-2024-2035-A-Forecasted-5-6-Billion-Landscape.html. Accessed 17 Feb 2025."},{"key":"3558_CR98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(24)02524-8","volume":"405","author":"RM Shapiro","year":"2025","unstructured":"Shapiro RM, Romee R. iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma. Lancet. 2025;405:98\u20139.","journal-title":"Lancet"},{"key":"3558_CR99","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405:127\u201336.","journal-title":"Lancet"},{"key":"3558_CR100","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","volume":"12","author":"P Strati","year":"2025","unstructured":"Strati P, Castro J, Goodman A, Bachanova V, Kamdar M, Awan FT, et al. Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. Lancet Haematol. 2025;12:e505\u201315.","journal-title":"Lancet Haematol"},{"key":"3558_CR101","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.2022016205","volume":"141","author":"F Cichocki","year":"2023","unstructured":"Cichocki F, van der Stegen SJC, Miller JS. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood. 2023;141:846\u201355.","journal-title":"Blood"},{"key":"3558_CR102","doi-asserted-by":"crossref","unstructured":"Bernareggi D, Gonsalves C, Schabla M, Garate-Carrilo A, El-Kalay M, Kaufman DS et al. A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy. Blood. 2022;140 Supplement 1:1613\u20134.","DOI":"10.1182\/blood-2022-163871"},{"key":"3558_CR103","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.","journal-title":"Mol Cancer"},{"key":"3558_CR104","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/cas.70008","volume":"116","author":"K Nishimura","year":"2025","unstructured":"Nishimura K, Aoki T, Kobayashi M, Takami M, Ozaki K, Ogawa K, et al. Antibody-Dependent cellular cytotoxicity of iPS Cell-Derived natural killer T cells by Anti-GD2 mAb for neuroblastoma. Cancer Sci. 2025;116:884\u201396.","journal-title":"Cancer Sci"},{"issue":"7Supplement","key":"3558_CR105","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1158\/1538-7445.AM2023-5667","volume":"83","author":"V Khairnar","year":"2023","unstructured":"Khairnar V, Waters C, Diaz S, De Franco D, Kadouche J, Teper D, et al. Abstract 5667: CYT-303 FLEX-NKTM engager dose response efficacy mechanisms in HCC tumor model and safety in cynomolgus monkey toxicology studies support clinical evaluation in hepato-cellular carcinoma. Cancer Res. 2023;83(7Supplement):5667\u20135667.","journal-title":"Cancer Res"},{"key":"3558_CR106","doi-asserted-by":"crossref","unstructured":"Lin L, Gao P, Chen A-P, Chang H-M, Ashok P, Zou D et al. Abstract 3187: Improved anti-tumor immune functions of iPSC-derived NK cells with TGF\u03b2R2 knock-out and\/or IL-15 knock-in by TALEN\u00ae editing for use alone or in combination with GPC3 Flex-NKTM bispecific antibody. Cancer Res. 2023;83 7_Supplement:3187\u20133187.","DOI":"10.1158\/1538-7445.AM2023-3187"},{"key":"3558_CR107","doi-asserted-by":"crossref","unstructured":"Chen A-P, Gao P, Ashok P, Ma MC, Zou D, Chambers A, et al. 323\u2005TALEN\u00ae -based gene edited iPSC-derived NK (iNK) cells demonstrate enhanced antitumor activity. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2022. pp. A339\u2013339.","DOI":"10.1136\/jitc-2022-SITC2022.0323"},{"key":"3558_CR108","doi-asserted-by":"crossref","unstructured":"Borges L, Wallet MA, Bullaughey C-L, Naso MF, Gurung B, Keating S et al. Development of Multi-Engineered iPSC-Derived CAR-NK Cells for the Treatment of B-Cell Malignancies. Blood. 2021;138 Supplement 1:1729\u20131729.","DOI":"10.1182\/blood-2021-148438"},{"issue":"Supplement 1","key":"3558_CR109","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2023-182313","volume":"142","author":"I Ramachandran","year":"2023","unstructured":"Ramachandran I, Rothman S, Clausi M, Mcfadden K, Salantes B, Jih G, et al. Multiple doses of Cnty-101, an iPSC-Derived allogeneic CD19 targeting CAR-NK Product, are safe and result in tumor microenvironment changes associated with response: A case study. Blood. 2023;142(Supplement 1):1654\u20131654.","journal-title":"Blood"},{"key":"3558_CR110","doi-asserted-by":"crossref","unstructured":"Perez A, Hall MS, Lu S, Peterka B, Naso M, Levitsky H et al. Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy. Blood. 2024;144 Supplement 1:4820\u20134820.","DOI":"10.1182\/blood-2024-210942"},{"key":"3558_CR111","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1158\/1538-7445.AM2024-4009","volume":"84 6Supplement","author":"MS Hall","year":"2024","unstructured":"Hall MS, Dower CM, Miller M, Wheeler J, Carton J, Manor O, et al. Abstract 4009: discovery of inhibitory CAR target DSG1 for damping NECTIN4 on-target off-tumor toxicity in iPSC-derived CAR-T cell therapy. Cancer Res. 2024;84 6Supplement:4009\u20134009.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"3558_CR112","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1182\/blood-2021-150731","volume":"138","author":"A Gerew","year":"2021","unstructured":"Gerew A, Sexton S, Wasko KM, Shearman MS, Zhang K, Chang K-H, et al. Deletion of CISH and TGF\u03b2R2 in iPSC-Derived NK cells promotes high cytotoxicity and enhances in vivo tumor killing. Blood. 2021;138(Supplement 1):2780\u20132780.","journal-title":"Blood"},{"key":"3558_CR113","doi-asserted-by":"crossref","unstructured":"Park JH, Jain N, Chen A, McGuirk JP, Diaz M, Valamehr B et al. A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed\/Refractory B-Cell Malignancies. Blood. 2020;136 Supplement 1:15\u20136.","DOI":"10.1182\/blood-2020-142423"},{"key":"3558_CR114","doi-asserted-by":"publisher","unstructured":"Hosking MP, Arimori T, Shirinbak S, Omilusik K, Chandra S, Bickers C, et al. 269\u2005Preferential targeting of HER2-expressing cancer cells by FT825\/ONO-8250, an off-the-shelf iPSC-derived CAR-T cell incorporating novel synthetic mechanisms for enhanced solid tumor activity. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2024. pp. A310\u2013310.\u00a0https:\/\/doi.org\/10.1016\/j.stem.2025.05.007.","DOI":"10.1016\/j.stem.2025.05.007"},{"issue":"13 Supplement","key":"3558_CR115","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1158\/1538-7445.AM2018-3576","volume":"78","author":"R Bjordahl","year":"2018","unstructured":"Bjordahl R, Mahmood S, Gaidarova S, Abujarour R, Clarke R, Stokely L, et al. Abstract 3576: FT500, an off-the-shelf NK cell cancer immunotherapy derived from a master pluripotent cell line, enhances T-cell activation and recruitment to overcome checkpoint Blockade resistance. Cancer Res. 2018;78(13 Supplement):3576\u20133576.","journal-title":"Cancer Res"},{"key":"3558_CR116","doi-asserted-by":"crossref","unstructured":"Bachanova V, Deol A, Al-Juhaishi TMS, Lulla PD, Byrne MT, Wong C et al. Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed\/Refractory B-Cell Lymphoma. Blood. 2024;144 Supplement 1:6543\u20136543.","DOI":"10.1182\/blood-2024-198684"},{"key":"3558_CR117","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/1538-7445.AM2021-1591","volume":"81 13Supplement","author":"J Goulding","year":"2021","unstructured":"Goulding J, Blum R, Hancock B, Ge M, Groff B, Shirinbak S, et al. Abstract 1591: FT536: preclinical development of a novel off-the-shelf CAR-MICA\/B NK cell immunotherapy combined with radiation and antibody treatments as a first-of-kind pan-cancer targeting strategy. Cancer Res. 2021;81 13Supplement:1591\u20131591.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"3558_CR118","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.1182\/blood-2022-166728","volume":"140","author":"M Juckett","year":"2022","unstructured":"Juckett M, Mailankody S, Eghtedar A, Bickers C, Zong X, Wong L, et al. A phase I study of FT538, an Off-the-Shelf, multiplexed-Engineered, iPSC-Derived NK cell therapy in combination with daratumumab in Relapsed\/Refractory multiple myeloma. Blood. 2022;140(Supplement 1):10327\u20138.","journal-title":"Blood"},{"issue":"12Supplement","key":"3558_CR119","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/1538-7445.AM2022-2761","volume":"82","author":"N Zorko","year":"2022","unstructured":"Zorko N, Cichocki F, Goulding J, Hancock B, Blum R, Pribadi M, et al. Abstract 2761: FT573: preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel Camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3. Cancer Res. 2022;82(12Supplement):2761\u20132761.","journal-title":"Cancer Res"},{"key":"3558_CR120","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1158\/1538-7445.AM2021-1550","volume":"81 13Supplement","author":"JP Goodridge","year":"2021","unstructured":"Goodridge JP, Bjordahl R, Mahmood S, Reiser J, Gaidarova S, Blum R, et al. Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma. Cancer Res. 2021;81 13Supplement:1550\u20131550.","journal-title":"Cancer Res"},{"key":"3558_CR121","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1158\/1538-7445.AM2024-1336","volume":"84 6Supplement","author":"S Matsumoto","year":"2024","unstructured":"Matsumoto S, Fujita Y, Goto K, Sato Y, Nishigaki F, Higashi Y, et al. Abstract 1336: verification of the effect of human allogeneic iPS cell-derived gene-engineered NK cells (eNK cells HLCN061) on mesothelioma. Cancer Res. 2024;84 6Supplement:1336\u20131336.","journal-title":"Cancer Res"},{"issue":"Suppl 2 Suppl 2","key":"3558_CR122","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/sctm.21-0135","volume":"10","author":"S-J Lu","year":"2021","unstructured":"Lu S-J, Feng Q. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients. Stem Cells Transl Med. 2021;10(Suppl 2 Suppl 2):S10\u20137.","journal-title":"Stem Cells Transl Med"},{"key":"3558_CR123","doi-asserted-by":"crossref","unstructured":"Cichocki F, Goodridge JP, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R et al. Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells. Blood. 2021;138 Supplement 1:407\u2013407.","DOI":"10.1182\/blood-2021-148654"},{"issue":"12Supplement","key":"3558_CR124","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1158\/1538-7445.AM2022-3151","volume":"82","author":"D Bernareggi","year":"2022","unstructured":"Bernareggi D, Gonsalves C, Schabla M, Garate-Carrilo A, O\u2019Gorman E, Chang N, et al. Abstract 3151: A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies. Cancer Res. 2022;82(12Supplement):3151\u20133151.","journal-title":"Cancer Res"},{"key":"3558_CR125","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/cas.14374","volume":"111","author":"T Ueda","year":"2020","unstructured":"Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, et al. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells. Cancer Sci. 2020;111:1478\u201390.","journal-title":"Cancer Sci"},{"key":"3558_CR126","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2024;390:584\u20136.","journal-title":"N Engl J Med"},{"key":"3558_CR127","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41586-024-01215-0","volume":"629","author":"C Willyard","year":"2024","unstructured":"Willyard C. Do cutting-edge CAR-T-cell therapies cause cancer? What the data say. Nature. 2024;629:22\u20134.","journal-title":"Nature"},{"key":"3558_CR128","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/d41591-023-00042-6","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho T. First two patients receive CAR T cell therapy for HIV. Nat Med. 2023;29:1290\u20131.","journal-title":"Nat Med"},{"key":"3558_CR129","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-Cell therapy in autoimmune Disease - A case series with Follow-up. N Engl J Med. 2024;390:687\u2013700.","journal-title":"N Engl J Med"},{"key":"3558_CR130","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402:2034\u201344.","journal-title":"Lancet"},{"key":"3558_CR131","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41586-023-06424-7","volume":"620","author":"S Buckberry","year":"2023","unstructured":"Buckberry S, Liu X, Poppe D, Tan JP, Sun G, Chen J, et al. Transient Naive reprogramming corrects hips cells functionally and epigenetically. Nature. 2023;620:863\u201372.","journal-title":"Nature"},{"key":"3558_CR132","doi-asserted-by":"publisher","unstructured":"Uenaka T, Napole AB, Saha AD, Sun D, Singavarapu A, Calzada L et al. Prevention of transgene Silencing during human pluripotent stem cell differentiation. BioRxiv. 2025.\u00a0https:\/\/doi.org\/10.1101\/2025.04.07.647695.","DOI":"10.1101\/2025.04.07.647695"},{"key":"3558_CR133","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41588-022-01147-3","volume":"54","author":"FJ Rouhani","year":"2022","unstructured":"Rouhani FJ, Zou X, Danecek P, Badja C, Amarante TD, Koh G, et al. Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells. Nat Genet. 2022;54:1406\u201316.","journal-title":"Nat Genet"},{"key":"3558_CR134","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature09805","volume":"471","author":"A Gore","year":"2011","unstructured":"Gore A, Li Z, Fung H-L, Young JE, Agarwal S, Antosiewicz-Bourget J, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:63\u20137.","journal-title":"Nature"},{"key":"3558_CR135","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature13551","volume":"511","author":"H Ma","year":"2014","unstructured":"Ma H, Morey R, O\u2019Neil RC, He Y, Daughtry B, Schultz MD, et al. Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature. 2014;511:177\u201383.","journal-title":"Nature"},{"key":"3558_CR136","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a hodgkin tumor model. Blood. 2009;113:6392\u2013402.","journal-title":"Blood"},{"key":"3558_CR137","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood.V97.1.63","volume":"97","author":"P Tiberghien","year":"2001","unstructured":"Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63\u201372.","journal-title":"Blood"},{"key":"3558_CR138","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells engineered with chimeric antigen receptors enhance Anti-tumor activity. Cell Stem Cell. 2018;23:181\u2013e1925.","journal-title":"Cell Stem Cell"},{"key":"3558_CR139","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-023-01455-z","volume":"16","author":"F Meng","year":"2023","unstructured":"Meng F, Zhang S, Xie J, Zhou Y, Wu Q, Lu B, et al. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells. J Hematol Oncol. 2023;16:62.","journal-title":"J Hematol Oncol"},{"key":"3558_CR140","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1089\/hum.2018.169","volume":"30","author":"S Pellenz","year":"2019","unstructured":"Pellenz S, Phelps M, Tang W, Hovde BT, Sinit RB, Fu W, et al. New human chromosomal sites with safe harbor potential for targeted transgene insertion. Hum Gene Ther. 2019;30:814\u201328.","journal-title":"Hum Gene Ther"},{"key":"3558_CR141","doi-asserted-by":"publisher","first-page":"17481","DOI":"10.1073\/pnas.0804788105","volume":"105","author":"A Kruschinski","year":"2008","unstructured":"Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA. 2008;105:17481\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3558_CR142","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","volume":"121","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology. 2007;121:258\u201365.","journal-title":"Immunology"},{"key":"3558_CR143","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051\u20137.","journal-title":"Blood"},{"key":"3558_CR144","doi-asserted-by":"publisher","first-page":"884648","DOI":"10.3389\/fimmu.2022.884648","volume":"13","author":"I Terr\u00e9n","year":"2022","unstructured":"Terr\u00e9n I, Orrantia A, Astarloa-Pando G, Amarilla-Irusta A, Zenarruzabeitia O, Borrego F. Cytokine-Induced Memory-Like NK cells: from the basics to clinical applications. Front Immunol. 2022;13:884648.","journal-title":"Front Immunol"},{"key":"3558_CR145","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s40425-019-0652-7","volume":"7","author":"YH Choi","year":"2019","unstructured":"Choi YH, Lim EJ, Kim SW, Moon YW, Park KS, An H-J. IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells. J Immunother Cancer. 2019;7:168.","journal-title":"J Immunother Cancer"},{"key":"3558_CR146","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2020.12.012","volume":"534","author":"M Liu","year":"2021","unstructured":"Liu M, Meng Y, Zhang L, Han Z, Feng X. High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochem Biophys Res Commun. 2021;534:149\u201356.","journal-title":"Biochem Biophys Res Commun"},{"key":"3558_CR147","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"3558_CR148","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, et al. Adoptive transfer of NKG2D CAR mRNA-Engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27:1114\u201325.","journal-title":"Mol Ther"},{"key":"3558_CR149","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083\u20139.","journal-title":"Am J Cancer Res"},{"key":"3558_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14:1.","journal-title":"Exp Hematol Oncol"},{"key":"3558_CR151","unstructured":"Regulation of Human Cells. Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) - Small Entity Compliance Guide | FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance. Accessed 3 Jun 2025."},{"key":"3558_CR152","unstructured":"ISSCR. ISSCR Guidelines for Stem Cell Research and Clinical Translation, Version 1.1. Guidelines for Stem Cell Research and Clinical Translation. 2021. https:\/\/www.isscr.org\/guidelines\/#toc. Accessed 26 May 2025."},{"key":"3558_CR153","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41536-022-00242-7","volume":"7","author":"J-H Kim","year":"2022","unstructured":"Kim J-H, Kawase E, Bharti K, Karnieli O, Arakawa Y, Stacey G. Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies. Npj Regen Med. 2022;7:54.","journal-title":"Npj Regen Med"},{"key":"3558_CR154","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcyt.2020.12.014","volume":"23","author":"RMT Ten Ham","year":"2021","unstructured":"Ten Ham RMT, Nievaart JC, Hoekman J, Cooper RS, Frederix GWJ, Leufkens HGM, et al. Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy. 2021;23:730\u20139.","journal-title":"Cytotherapy"},{"key":"3558_CR155","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11899-019-00522-y","volume":"14","author":"D Smith","year":"2019","unstructured":"Smith D, Heathman TRJ, Klarer A, LeBlon C, Tada Y, Hampson B. Towards automated manufacturing for cell therapies. Curr Hematol Malig Rep. 2019;14:278\u201385.","journal-title":"Curr Hematol Malig Rep"},{"key":"3558_CR156","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jcyt.2024.05.022","volume":"26","author":"M Madrid","year":"2024","unstructured":"Madrid M, Lakshmipathy U, Zhang X, Bharti K, Wall DM, Sato Y, et al. Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC committee. Cytotherapy. 2024;26:1382\u201399.","journal-title":"Cytotherapy"},{"key":"3558_CR157","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/pr9020240","volume":"9","author":"B Nie\u00dfing","year":"2021","unstructured":"Nie\u00dfing B, Kiesel R, Herbst L, Schmitt RH. Techno-Economic analysis of automated iPSC production. Processes. 2021;9:240.","journal-title":"Processes"},{"key":"3558_CR158","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","volume":"11","author":"Z Jackson","year":"2020","unstructured":"Jackson Z, Roe A, Sharma AA, Lopes FBTP, Talla A, Kleinsorge-Block S, et al. Automated manufacture of autologous CD19 CAR-T cells for treatment of Non-hodgkin lymphoma. Front Immunol. 2020;11:1941.","journal-title":"Front Immunol"},{"key":"3558_CR159","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41551-024-01219-1","volume":"8","author":"W-X Sin","year":"2024","unstructured":"Sin W-X, Jagannathan NS, Teo DBL, Kairi F, Fong SY, Tan JHL, et al. A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells. Nat Biomed Eng. 2024;8:1571\u201391.","journal-title":"Nat Biomed Eng"},{"key":"3558_CR160","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","volume":"59","author":"N Albinger","year":"2024","unstructured":"Albinger N, M\u00fcller S, Kostyra J, Kuska J, Mertlitz S, Penack O, et al. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transpl. 2024;59:489\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"3558_CR161","doi-asserted-by":"publisher","first-page":"26678","DOI":"10.1038\/s41598-024-76791-2","volume":"14","author":"F Jahan","year":"2024","unstructured":"Jahan F, Penna L, Luostarinen A, Veltman L, Hongisto H, L\u00e4hteenm\u00e4ki K, et al. Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts. Sci Rep. 2024;14:26678.","journal-title":"Sci Rep"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03558-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T21:03:01Z","timestamp":1767042181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03558-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":161,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3558"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03558-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}